Europeans plan new gravitational wave observatory in space
The European Space Agency (ESA) and the space company OHB based in the German city of Bremen have now signed an important contract for the Laser Interferometer Space Antenna (LISA) mission at the Paris Airshow, an OHB spokeswoman announced on Tuesday.
OHB has been awarded the contract as the main contractor for the construction of the observatory, she said, adding that the contract is worth €839 million ($963 million). The Bremen-based company plans to build the observatory together with partners.
The core of the mission is a constellation of three spacecraft, which will follow Earth in its orbit around the sun in the form of an equilateral triangle with sides of 2.5 million kilometres.
Each spacecraft is to carry free-floating test masses made of a gold-platinum alloy.
In space, gravitational waves distort spacetime and thus also minimally change the distances between the test masses, OHB said.
The mission is led by the ESA. It is a collaboration between ESA, its member states, the US space agency NASA, and an international consortium of scientists.
'Einstein himself would be proud'
"As the first space mission designed to capture gravitational waves, LISA will open a brand-new window on the dark universe and test the known laws of physics to their extreme," said ESA's Director of Science Carole Mundell, according to the announcement.
According to the chief executive of OHB System AG, Chiara Pedersoli, the observatory will enable scientists to see the universe with new eyes. "Personally, I am certain [Albert] Einstein himself would be proud to witness how mankind continues to build upon his legacy by proofing his theory."
The launch of the mission is planned for mid-2035.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
30 minutes ago
- Epoch Times
Houston, ‘We've Had a Problem': Jim Lovell and Apollo 13
On Aug. 7, 2025, Jim Lovell died at the age of 97. A Naval aviator and a test pilot, he joined the National Aeronautics and Space Administration's (NASA) training program for crewed flights in 1962. On his Gemini 7 flight, he and fellow astronaut Frank Borman set a record for the longest number of days spent in space and for the first time rendezvoused with another spacecraft. Later he was aboard Gemini 12 with Buzz Aldrin, the last flight of the Gemini series.
Medscape
30 minutes ago
- Medscape
Pricey Drugs Unlikely to Solve Dementia
This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease. Biomarkers and Lifestyle We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology . A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. Just to give you an example, there is one study from the US published in Neurology with more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. Herpes Zoster and Cognitive Impairment There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated relative risk reduction for dementia was 20%. Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%. GLP-1 Drugs and Anti-Amyloids We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists. Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities. At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies. With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. Spend Money on Lifestyle At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle. I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on. Dear colleagues, this is a short update on what has happened recently in the field of dementia. I'm Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.
Yahoo
an hour ago
- Yahoo
Small NASA radar system tracks millimeter terrain and volcanic changes without GPS
A collaboration between NASA and small aerospace company Aloft Sensing has produced a compact radar system capable of detecting minute changes in Earth's surface. The instrument, called HALE InSAR, is small, lightweight, and consumes less than 300 watts—roughly the power of an electric bike—yet can track millimeter-scale deformations in terrain, snowpacks, and volcanoes. What sets HALE InSAR apart is its ability to operate without GPS, using advanced positioning algorithms to locate itself with unprecedented accuracy. 'SAR is like a long-exposure camera, except with radio waves,' explained Brian Pollard, Chief Engineer at Aloft Sensing. 'Precise positioning is critical, or your image smears.' Flying high for science HALE InSAR rides aboard high-altitude, long-endurance (HALE) platforms—lightweight aircraft designed to stay aloft for weeks, months, or even years. These vehicles can revisit the same location multiple times per hour, making them ideal for monitoring subtle changes in Earth's geologic environment. Interferometric Synthetic Aperture Radar (InSAR), the technology behind the system, compares repeated radar images to detect surface shifts. Traditional InSAR instruments are too large for HALE vehicles, but HALE InSAR weighs under 15 pounds and features a flat phased-array antenna. This allows operators to steer the radar beam electronically, eliminating bulky gimbals and other heavy components. By tracking millimeter-scale shifts, HALE InSAR could provide early warnings for natural disasters like volcanic eruptions or landslides. Its GPS-free navigation also makes it suitable for remote locations, increasing its utility for national security and scientific missions alike. Lauren Wye, CEO of Aloft Sensing, highlighted the instrument's advantages: 'It's a level of sensitivity that has eluded traditional radar sensors, without making them bulky or expensive. This technology has huge benefits for science and civil applications.' From balloons to space HALE InSAR has already been validated on airships flying at 65,000 feet and on small stratospheric balloons. Next, the team plans to test it aboard fixed-wing HALE aircraft. In the future, the instrument could even be deployed on small satellites in low Earth orbit, expanding its reach beyond the stratosphere. The project was made possible through NASA's Earth Science Technology Office (ESTO), with previous funding supporting its novel electronically steered antenna and agile software-defined transceiver. This 'hand-in-hand' approach has allowed Aloft Sensing, a small business, to bring a prototype to a proven instrument, attracting both civil and military interest. HALE InSAR represents a leap forward in compact radar technology, merging high-altitude endurance, GPS-independent positioning, and millimeter-scale precision. For researchers and agencies monitoring Earth's dynamic systems, this small but mighty radar could change how we watch our planet in real time. Solve the daily Crossword
